History
The Company's origins date back to 1927 when Dr. Ruhland Nachfolger GmbH was established in Germany as a manufacturer and supplier of surgical sutures. Already working with natural substances, the company branched into collagen and the CollaRx® technology was developed. Key events for the company include:
| 1985: | First launch of CollaRx® Gentamicin Surgical Implant in Europe under license to Schering Plough. |
| 1992: |
Company acquired by Rolf and Bill Schmidt.
Divested suture business and company name changed to Innocoll.
|
| 1998: | Second manufacturing facility established in South Africa. |
| 2003: |
Michael Myers appointed as CEO.
Company's business model changed from Contract Manufacturer to Speciality Pharmaceutical.
|
| 2004: |
Innocoll Technologies established.
Company begins R&D activities on selected internal and client funded product pipeline.
|
| 2005: |
Global registration and marketing rights to CollaRx Gentamicin Surgical Implant acquired from Schering Plough.
Innocoll Pharmaceuticals established as European sales and marketing division.
|
| 2006: | Innocoll sponsors its first human clinical trial evaluating CollaRx® Bupivacaine Surgical Implant for the treatment of post-operative pain. First IND filed: CollaRx® Gentamicin Topical to treat infected diabetic foot ulcers. First US Approval: CollaGUARD™. |
| 2007: |
IND filed for CollaRx Bupivacaine Surgical Implant; product commenced phase II clinical trials in the US.
IND filed for CollaRx Gentamicin Surgical Implant; product commenced phase III trials in the US.
IND filed for CollaRx Bupivacaine Topical for the treatment of painful chronic skin ulcers and burns. Commenced phase II clinical trials for the CollaRx Gentamicin Topical in the US. Divested European sales and marketing infrastructure to EUSA. Series A fund raising completed. |
| 2008: | Commenced two phase III clinical trials in the US for CollaRx Gentamicin Surgical Implant in cardiac and colorectal surgery. Commenced two phase II clinical trials in the US for CollaRx Bupivacaine Surgical Implant in hysterectomy and hernia repair surgeries. Commenced two additional phase II clinical trials in the US for CollaRx Gentamicin Topical for the Treatment of Moderately Infected Diabetic Foot Ulcers and also for the Prevention of Diabetic Foot Infections. |